Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 15/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623232 | 0.82 | PDE3B (0.48) | LMNA | |
| Hydrochloric Acid SCHEMBL1283814 | 0.81 | PDE3B (0.47) | LMNA | |
| SCHEMBL1625215 | 0.80 | LMNA (0.51) | TP53MAPTLMNA | |
| SCHEMBL1625569 | 0.80 | TP53 (0.46) | PTGESTP53MAPTLMNA | |
| SCHEMBL1625057 | 0.80 | EPHX2 (0.47) | PTGESTP53MAPT | |
| SCHEMBL1623592 | 0.79 | LMNA (0.52) | TP53MAPTLMNA | |
| SCHEMBL1284041 | 0.76 | PYGL (0.44) | LMNA | |
| SCHEMBL1625051 | 0.75 | F10 (0.46) | TP53MAPTLMNA | |
| SCHEMBL1624785 | 0.74 | PDE3B (0.47) | MAPTLMNA | |
| Hydrochloric Acid SCHEMBL1283850 | 0.73 | PDE3B (0.46) | MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835648-B2 | Hedgehog pathway antagonists and therapeutic applications thereof | SIENA BIOTECH S.P.A. (IT) | 2014-09-16 | — | — | US | disclosed |
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SIENA BIOTECH S.P.A. (IT) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088752-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND THERAPEUTIC APPLICATIONS THEREOF | SHH, GLI1, SMO | PTGES 2679/4885PTGS2 1886/4885TP53 537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.